Loading market dashboard
Agree Realty Corporation
ADCReal EstateNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Inflation relentlessly erodes purchasing power, making dividend growth essential for income investors to maintain real income. A barbell strategy—combining moderate-yielding dividend growth stocks/ETFs and 6.5%+ yielding investment grade preferreds—offers both growth and current income. AI-driven capex by large-cap S&P 500 firms is powering economic growth and masking weakness among lower-income consumers.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
REITs (XLRE) may face another sector-wide pullback due to rising bond yields and inflation driven by Middle East conflict. CareTrust REIT and Agree Realty stand out for quality, growth, and strong balance sheets, but current valuations demand patience. CareTrust REIT stands out for its strong acquisition-driven growth, investment-grade upgrade, and robust balance sheet but is currently expensive at 19.63x earnings.
Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential
ADC Therapeutics shares slumped nearly 53% in premarket trading on Thursday after a late-stage study testing its blood cancer drug showed more deaths among treated patients, despite meeting its main goal of improving progression-free survival.
Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor â palbociclib
ADC remains a hold due to its still-elevated valuation despite robust business fundamentals and portfolio quality. ADC boasts a high share of investment-grade tenants (over 65%) and strong sector diversification, with Walmart as its largest tenant at 5.7% ABR. Management highlights a fortress balance sheet, $2.3B liquidity, and no material debt maturities until 2028, supporting continued external growth.
Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neur
Thirty-three US REITs utilized their at-the-market (ATM) offering programs during the recent quarter, raising $4.15 billion in aggregate proceeds. Healthcare REIT Welltower Inc. raised the most capital during the first quarter, selling nearly 7.7 million shares of common stock through its ATM program for $1.56 billion in gross proceeds. In the aggregate, healthcare REITs raised $2.67 billion through their ATM programs during the first quarter, the most of any property sector. The data center REIT sector was next with $875.0 million.
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk's ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-007 Trials-in-Progress Poster to be Presented at ASCO MORRISTOWN, N.J., May 21, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it entered into a new option agreement with Hangzhou DAC for access to CPT113 for use in up to five additional ADC programs.
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates ("ADC") development pipeline. The Company has strengthened its purification, analytical characterization, conjugation development, and quality control ("QC") capabilities, while enhancing cellular testing and potency evaluation workflows within a more structured stage-gated framework to better support the advancement of its ADC partnership programs.
AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadj
Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] after selling FYARRO and rebranding from Aadi Bioscience. I downgrade WHWK from 'Strong Buy' to 'Hold' due to the early-stage pipeline, competitive landscape, and unproven efficacy/safety of modified ADCs. Key catalysts include phase 1 data readouts for HWK-007 and HWK-016 in 1H 2027 and an IND filing for HWK-206 in mid-2026.
Fosun Pharma and AriBio Sign Exclusive Global Option Agreement for AR1001 for the Treatment of Alzheimer's Disease PR Newswire
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The dividend is payable June 12, 2026 to stockholders of.
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value oncology indications
BEIJING, May 06, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208. CDH17 is a calcium-dependent cell adhesion protein that plays a key role in tumor cell proliferation, migration, and metastasis.
PARIS--(BUSINESS WIRE)--Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solution.
ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026.
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.
Agree Realty (ADC) continues to outperform peers, demonstrating resilient growth despite higher interest rates and economic uncertainty. ADC reported robust Q1 results: 8% AFFO and core FFO growth, $424M invested at a 7.1% cap rate, and a 99.7% occupancy rate. With an A-rated balance sheet, low leverage (3.2x pro forma), and strong liquidity, ADC is well-positioned for accelerated growth as rates decline.
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initiate in second half of 2026 Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China CR-002, a PD-L1-targeted ADC, on track to enter the clinic in second half of 2026 Multiple key clinical data readouts anticipated beginning in Q1 2027 WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights.
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.
Agree Realty remains a Buy, supported by strong Q1 results, a robust investment pipeline, and prudent management amid macro uncertainty. ADC posted 7.9% AFFO per share growth in Q1, reaffirmed 2026 guidance, and maintains an attractive financial position. The monthly dividend was raised to $0.267 (4.15% yield), with a ~70% payout ratio based on their AFFO guidance, while preferred shares (ADC.PR.A) offer an attractive 6.21% yield.
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
The 10-year Treasury yield sits at 4.26% and the Fed funds rate has been held at 3.75% for more than four months.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Agree Realty Corporation (ADC) Q1 2026 Earnings Call Transcript
Agree Realty (ADC) came out with quarterly funds from operations (FFO) of $1.14 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to FFO of $1.06 per share a year ago.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended March 31, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. First Quarter 2026 Financial and Operating Highlights: Invested approximately $424 million in 100 retail net lease properties 15 development or Developer Funding Platform ("DFP") projects completed or under construction with anticipated total cos.
Results from early clinical studies across Junshi Biosciences' innovative pipeline were presented at the 2026 AACR, featuring: JS212 (EGFR/HER3 ADC), the J
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the latest preclinical data for three proprietary pipeline assets at the American Association for Cancer Research (AACR) Annual Meeting (from April 17 to 22), including CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology Platform All three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed utilizing CStone's proprietary ADC technology platform, which incorporates the following core features: High Stability & Precise Payload Release: The platform utilizes CStone's proprietary CSL20 linker, a hydrophilic construct designed for enhanced stability in circulation.
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across various cancer models at low single ‑ digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC) Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 MORRISTOWN, N.J., April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA.
Realty Income and VICI Properties are highlighted as top net lease REITs with wide moats and attractive valuations. Net lease REITs benefit from long-term, predictable cash flows and cost-of-capital advantages, especially those with access to European debt markets. O trades at 15.1x P/AFFO (below its historical 17.7x), offers a 5.0% yield, and is forecasted for a 15% 12-month total return.
Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options Onvansertib in combination with trastuzumab deruxtecan demonstrated enhanced antitumor activity, including tumor regression and apoptosis in HER2-low breast cancer models, supporting its potential for patients with limited treatment options
Passive income is revenue generated without the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.
High yields often hide trouble, and blue chips can still be overpriced. The best REITs are often quality names facing temporary issues. These REITs may offer yield and upside today.
Ingelheim, Germany and Shanghai , China /Cambridge, Mass. – 15 April , 202 6 – Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab's DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently need more effective treatment options.
INCHEON, Korea--(BUSINESS WIRE)-- #ADC--Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis's first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an open‑label, multi-center, first‑in‑human trial to evaluate the safety, tolerability an.
U.S. equity markets extended their rebound this week as investors welcomed tentative progress toward de-escalation in the Middle East following several days of dramatic threats of significant escalation. The fragile pause in hostilities temporarily eased fears of a prolonged disruption to global energy supplies and fueled a sharp retreat in oil prices after a surge to four-year highs. Markets also found support from lukewarm inflation data and signs that the U.S. labor market continues to demonstrate resilience despite elevated energy costs and geopolitical uncertainty.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.267 per common share, representing a 1.9% month-over-month increase. The monthly dividend reflects an annualized dividend amount of $3.204 per common share, representing a 4.3% increase over the annualized dividend amount of $3.072 per common share from the second quarter of 2025. The divid.
I achieved a record $912.86 in monthly dividends and added $308.68 in forward income, reaching $6,883.46 in annual projected dividends. New capital contributions and purchases, particularly in SPYI and ADC, drove forward income growth this month. My portfolio yield on cost stands at 4.83% versus a current yield of 3.77%, reflecting disciplined accumulation and reinvestment.
Gladstone Capital offers a 10.1% well-covered monthly yield, trading at a 15% discount to NAV with strong balance sheet and low non-accruals. GLAD's portfolio is anchored in secured debt, avoids software and AI exposure, and benefits from PE sponsor backing and reshoring trends. Agree Realty Preferred A provides a 6.2% monthly yield, trades at a 31% discount to par, and offers cumulative dividend protection.
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026
REITs deserve a larger allocation today, driven by attractive valuations, structural demand, and reliable income across diverse sectors. Data center REITs like Equinix, Digital Realty, and Iron Mountain benefit from AI and cloud-driven demand, with strong growth and supply scarcity. Industrial REITs such as Prologis, EastGroup, and STAG Industrial offer structural growth, with EastGroup favored for its Sunbelt focus and robust internal growth.
Shares of Agree Realty Corporation (NYSE: ADC - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating
Agree Realty Corporation (ADC) maintains a healthy investment spread, earning a 7.2% cap rate versus a 6.24% WACC, supporting accretive growth. ADC's muted beta of 0.72 and investment-grade tenant mix enhance risk-adjusted returns, distinguishing it within the net-lease REIT sector. Despite premium attributes, ADC currently trades near its justified enterprise value to invested capital premium (34% vs. 37%), indicating fair valuation.
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its first quarter 2026 operating results after the market closes on Tuesday, April 21, 2026. A conference call to discuss the Company's operating results is scheduled for Wednesday, April 22, 2026, at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (800) 715-9871 International (646) 307-196.
Here is how Agree Realty (ADC) and ANZ Group Holdings Limited - Sponsored ADR (ANZGY) have performed compared to their sector so far this year.
Exchange Traded Concepts LLC lessened its stake in shares of Agree Realty Corporation (NYSE: ADC) by 45.2% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 46,704 shares of the real estate investment trust's stock after selling 38,465 shares during the period. Exchange Traded Concepts
While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.
HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC. The studies will evaluate these two novel ADC candidates in combination with the Company's pioneering immuno-oncology (IO) 2.0 bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), as well as other proprietary high-potential anti-tumor assets, including AK117 (anti-CD47 monoclonal antibody) and AK109 (anti-VEGF monoclonal antibody), across a spectrum of advanced solid tumors.
ADC's recent pullback left investors wondering whether it's time to buy more shares or realize profits. ADC's triple net lease model and monthly dividends often draw comparisons to O, yet ADC offers distinct advantages (and one risk compared to O). Recent inflation data and higher-than-expected PPI readings have heightened market concerns, especially for REITs like ADC.
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity
Agree Realty Corporation remains a Buy, supported by a high-quality, diversified net lease portfolio and peer-leading investment-grade tenant exposure. ADC projects 2026 AFFO per share of $4.54–$4.58, targeting 5.4% growth at midpoint, with a robust pipeline and minimal near-term debt maturities. Despite macro headwinds and sector pressure, ADC's strong balance sheet, 99.7% occupancy, and disciplined capital allocation position it for solid returns.
Top REIT investors are quietly repositioning their portfolios, revealing where the “smart money” sees opportunity. Several clear sector themes are emerging from recent 13F filings. But the biggest surprise may be how much top managers disagree on certain REITs.
